Is Diamox (acetazolamide) available as eye drops?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diamox (Acetazolamide) Formulations

No, Diamox (acetazolamide) does not come as eye drops—it is only available as oral tablets or sustained-release capsules for glaucoma treatment. 1

Available Formulations

Acetazolamide is classified as an oral carbonic anhydrase inhibitor used for decreasing aqueous humor production in glaucoma management. 1

The medication comes in:

  • 250 mg tablets taken four times daily 2
  • 500 mg sustained-release capsules taken once or twice daily 2

Why Not Eye Drops?

The development of topical acetazolamide formulations has been limited by significant pharmaceutical barriers:

  • Poor ocular bioavailability due to inadequate corneal penetration 3
  • Poor biphasic solubility that prevents effective eye drop formulation 3
  • While experimental complexes (ACZ:HP-beta-CD:TEA) have been studied to improve topical delivery, these remain investigational and are not commercially available 3

Topical Alternatives Available

If topical carbonic anhydrase inhibition is desired, FDA-approved topical formulations include:

  • Dorzolamide (topical carbonic anhydrase inhibitor) 1
  • Brinzolamide (topical carbonic anhydrase inhibitor) 1

These topical agents provide 15-20% IOP reduction compared to acetazolamide's 20-30% reduction, but avoid systemic side effects. 1

Clinical Efficacy Comparison

Research demonstrates that oral acetazolamide remains more effective than topical alternatives:

  • In pediatric glaucoma patients, switching from oral acetazolamide to topical dorzolamide resulted in a mean IOP increase of 3.7 mm Hg (20.2% increase), with all 11 eyes showing worse control on the topical agent 4
  • Oral acetazolamide achieved 35.7% IOP reduction versus 27.4% with topical dorzolamide 4

Important Clinical Caveat

When prescribing oral acetazolamide, be aware of significant systemic side effects including Stevens-Johnson syndrome, malaise, depression, electrolyte imbalances, renal calculi, and blood dyscrasias. 1 The medication is contraindicated in sulfonamide allergy, kidney stones, aplastic anemia, and sickle cell disease. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Acetazolamide dosage forms in the treatment of glaucoma.

Archives of ophthalmology (Chicago, Ill. : 1960), 1980

Research

Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.